Genome-wide association study and genomic risk prediction of age-related

macular degeneration in Israel

Michelle Grunin¹, Daria Triffon², Gala Beykin¹, Elior Rahmani^{3,4}, Regev Schweiger³, Liran Tiosano¹, Samer 3 4 Khateb¹, Shira Hagbi-Levi¹, Batya Rinsky¹, Refael Munitz¹, Thomas W Winkler⁷, Iris M Heid⁷, Eran 5 Halperin^{3,5,6}, Shai Carmi^{2*}, Itay Chowers^{1*} 6 ¹ Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 7 ² Braun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel 8 ³ Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel 9 ⁴ Department of Computer Science, University of California, Los Angeles, Los Angeles, CA, USA 10 ⁵ Department of Anesthesiology, University of California, Los Angeles, Los Angeles, CA, USA 11 ⁶ Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA 12 ⁷ Department of Genetic Epidemiology, University of Regensburg, Regensburg, Germany 13 *Indicates equal contribution 14 This work was supported by a grant from the Israel Science Foundation: 3485/19 to I.C. and S.C. The contribution of the 15 International AMD Genomics Consortium (IAMDGC) was supported by a grant from NIH (R01 EY022310). Genotyping was 16 supported by a contract (HHSN2682012000081) to the Center for Inherited Disease Research. MG is supported by a grant from

17

18

1

2

- 19 Itay Chowers, MD*
- 20 Department of Ophthalmology

For Correspondence:

21 Hadassah – Hebrew University Medical Center

the Bright Focus Foundation (M2021006F).

- 22 POB 12000, Jerusalem, Israel, 91120
- 23 Tel: +972-50-8573361

- 24 Fax: +972-2-6777228
- 25 Email: chowers@hadassah.org.il
- 26 Shai Carmi, PhD*
- 27 Braun School of Public Health and Community Medicine
- The Hebrew University of Jerusalem, Israel
- 29 POB 12271, Jerusalem, Israel, 9112102
- 30 Tel: +972-2-6758738
- 31 Email: shai.carmi@huji.ac.il

Abstract

32

33 Purpose: The risk of developing age-related macular degeneration (AMD) is influenced by genetic 34 background. In 2016, International AMD Genomics Consortium(IAMDGC) identified 52 risk variants in 34 35 loci, and a polygenic risk score(PRS) based on these variants was associated with AMD. The Israeli 36 population has a unique genetic composition: Ashkenazi Jewish(AJ), Jewish non-Ashkenazi, and Arab 37 sub-populations. We aimed to perform a genome-wide association study(GWAS) for AMD in Israel, and 38 to evaluate PRSs for AMD. 39 Methods: For our discovery set, we recruited 403 AMD patients and 256 controls at Hadassah Medical 40 Center. We genotyped all individuals via custom exome chip. We imputed non-typed variants using 41 cosmopolitan and AJ reference panels. We recruited additional 155 cases and 69 controls for validation. 42 To evaluate predictive power of PRSs for AMD, we used IAMDGC summary statistics excluding our study 43 and developed PRSs via either clumping/thresholding or LDpred2. 44 Results: In our discovery set, 31/34 loci previously reported by the IAMDGC were AMD associated with 45 P<0.05. Of those, all effects were directionally consistent with the IAMDGC and 11 loci had a p-value under Bonferroni-corrected threshold(0.05/34=0.0015). At a threshold of 5x10⁻⁵, we discovered four 46 47 suggestive associations in FAM189A1, IGDCC4, C7orf50, and CNTNAP4. However, only the FAM189A1 48 variant was AMD associated in the replication cohort after Bonferroni-correction. A prediction model 49 including LDpred2-based PRS and other covariates had an AUC of 0.82(95%CI:0.79-0.85) and performed 50 better than a covariates-only model(P=5.1x10⁻⁹). 51 Conclusions: Previously reported AMD-associated loci were nominally associated with AMD in Israel. A 52 PRS developed based on a large international study is predictive in Israeli populations.

Introduction

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population. The risk for developing AMD is strongly associated with the genetic background of the individual ^{1,2}. In 2005, AMD was the first disease for which genome-wide association studies (GWASs) have identified risk variants ^{3,4}. Via a seminal paper published in 2016, the International Age-Related Macular Degeneration Genomics Consortium (IAMDGC) has reported the genotyping of more than 30,000 AMD patients and controls of European ancestry and the discovery of 52 risk variants across 34 loci ². Israel is home to a number of populations of distinct genetic ancestry, including Ashkenazi Jews, non-Ashkenazi Jews – predominantly North-African Jews and Middle-Eastern Jews, and Arabs – predominantly Palestinians, Bedouins, and Druze. These populations are genetically diverse, having genetic ancestry related to the Middle East, Africa, and Europe, with variable mixture proportions 5-8. Some of the populations have experienced recent population-specific genetic drift due to founder events and endogamy 7,9,10 The unique genetic background of the Israeli populations suggests that the genetic architecture of AMD might be different in these populations compared to Europeans. In addition, the Israeli populations that have experienced strong genetic drift may harbor deleterious risk variants at a considerable frequency. This will increase power for discovering novel risk variants 11 as previously observed for other retinal diseases ^{12–14}. Previous studies of the genetic basis of AMD in Israel found that the most prominent risk variants – the genes CFH 15 and HTRA1/ARMS2 16 – were associated with AMD. However, the C2 locus, one of the top risk loci worldwide, was not associated with AMD in Israel ¹⁷. The 2016 study of the IAMDGC included an Israeli cohort. However, it was analyzed jointly with the other studies, which was uninformative about Israeli-specific genetic architecture and risk variants. Searching for population-specific risk variants is important even beyond the population under study, as any discovered variants and biological pathways may provide insight into the pathogenesis of the disease.

Polygenic risk scores (PRSs) were recently developed for numerous diseases based on the results of large-scale GWASs ¹⁸. A PRS is the count of risk alleles carried by an individual, where each allele is weighted by its effect size (usually the log odds-ratio), as estimated by GWAS. While PRSs cannot unambiguously distinguish healthy and affected individuals (due to the small proportion of variance in disease liability they explain), individuals at the top PRS quantiles are at a particularly high risk ^{19,20}. These individuals can then be subjected to personalized screening or prevention. A number of recent papers have developed or examined PRSs for AMD, showing that the PRS has considerable power to predict disease status and disease progression ^{2,21,22}. However, it is known that PRS accuracy can substantially decrease when evaluated in populations or ancestries other than the ones used for the original GWAS (usually European populations and ancestries) ^{23,24}. So far, no study has examined the accuracy of an AMD PRS in any of the Israeli sub-populations, which forms a barrier to the implementation of DNA-based risk stratification. In this paper, we used data on 558 AMD cases and 325 controls to investigate the genetic basis of AMD in the Israeli populations. Our study had three main goals. (1) To determine whether previously identified risk variants (from the IAMDGC 2016 GWAS) are associated with AMD in Israel, either across all Israeli sub-populations or in a population-specific manner. (2) To discover putative new AMD risk variants by running a GWAS in the Israeli study, anticipating that despite the small sample size, we may be able to identify risk variants that have drifted to high frequencies in the Israeli founder populations. (3) To evaluate the accuracy in the Israeli population of a PRS generated based on the IAMDGC GWAS. We show that the vast majority of previously discovered risk variants are also associated with AMD in Israel, Accordingly, a PRS based on previously discovered variants has high predictive power. While our study was too small for discovering new risk variants at a genome-wide significance level, our study suggested a number of putative associations at an attenuated significance threshold.

100

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

Results

Replication of known AMD loci

A previous large-scale AMD GWAS by the IAMDGC (n=33,976 ²) has discovered 34 associated loci. We examined the association of these loci with AMD status in our Israeli discovery set (403 AMD cases and 256 controls). Using the SNP with the lowest p-value in each locus, we found that most loci (31/34) were associated with AMD at a nominal significance level of P<0.05 with a direction of effect consistent with that of the IAMDGC (Supplementary Tables 2 and 3). The number of loci associated at the Bonferroni correction threshold (0.05/34=0.0015) was 11/34 (Supplementary Table 2). The top ranked loci were *CFH* (P=1.6·10⁻⁹) and nearby loci on chr1, and *ARMS2/HTRA1* (P=3.4·10⁻⁹, 5.1·10⁻⁹, respectively). The next significant locus was near *SYN3* (P=5.7·10⁻⁵). We note that replication was to some extent expected, given that the majority of the Israeli cohort was included in the IAMDGC. Association statistics for the known AMD risk loci for AJ (242 cases and 136 controls) and Arabs (36 cases and 30 controls) are reported in Supplementary Tables 4 and 5.

Discovery GWAS

We next ran a GWAS in our discovery set (AMD cases: n=403, controls: n=256). No novel variant was associated at the genome-wide significance threshold of $5\cdot10^{-8}$. Setting a more liberal threshold of $5\cdot10^{-5}$, and excluding variants in known risk loci, we identified four suggestive associations in the genes *C7orf50*, *IGDCC4*, *FAM189A1*, and *CNTNAP4* (Table 1; Figure S2). None of these SNPs were associated with AMD in the IAMDGC data ($P \ge 0.04$, Table 1). The variant rs116928937 in *IGDCC4* is exonic. Its allele frequency in European Americans was 1.23% (In the exome variant server), compared to 2.66% here. It is a missense variant (c.3188G>T), and according to Polyphen 25 it is "probably-damaging".

n=69 controls (Supplementary Table 1). We applied a Bonferroni corrected threshold of 0.05/4=0.0125.

Only the SNP in *FAM189A1* (rs1195500, chr15:29687047) replicated in the Israeli population (P<0.0001 in Fisher's exact test in both genotype and allele testing). The SNP rs12701455 (*C7orf50*) attained a p-value of 0.029 in the genotype-based test (Supplementary Table 1).

Evaluating a polygenic risk score for AMD

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

We developed polygenic risk scores (PRSs) for AMD in Israel based on the results of the IAMDGC GWAS and using two methods. The first method is clumping and thresholding (C+T), in which the most strongly associated SNP is retained from each LD block, as long as its p-value is under a threshold. The second method is LDpred2, which accounts for the influence of LD on effect sizes and incorporates a non-zero prior probability for having null effects. We generated nine C+T PRSs, corresponding to different p-value thresholds (exponentially increasing between 5·10⁻⁸ and 1), and four LDpred2 PRSs, corresponding to different values of the proportion of SNPs with non-zero effects and a sparsity parameter. For each PRS, we used logistic regression to predict AMD status based on age, sex, the first two principal components (a proxy of ancestry), and the PRS. We also fit a logistic regression model with covariates only. We used 5-fold cross-validation to evaluate the accuracy of the various models, which we quantified using AUC (the area under the receiver operator curve (ROC)). We compare the ROCs of the top C+T model, the top LDpred2 model, and the covariates-only model in Figure 1. For C+T, the AUC was highest (0.79; 95% confidence interval (CI): 0.75-0.82) for the most stringent p-value threshold (5·10⁻⁸), for a PRS that included 360 variants. Interestingly, the AUC decreased monotonically with increasing p-value thresholds (Figure S3). The top LDpred2 model (parameters p=0.056 and sparsity on) had a slightly higher AUC (0.82; 95% CI: 0.79-0.85) than the top C+T model. The covariates-only model had a significantly lower AUC (0.72; 95% CI: 0.69-0.76). This was also confirmed by DeLong's test for two correlated ROC curves (P=5.1·10⁻⁹). Overall, our results suggest that including the PRS in the prediction model improves accuracy.

We show the distribution of the top LDpred2 PRS in cases and controls in Figure 2A. The PRS distribution is different between cases and controls; however, considerable overlap exists. In Figure 2B, we plot the proportion of cases in each quintile of the LDpred2 PRS, demonstrating that the proportion of cases steadily increases with increasing quintiles. Finally, we used Spearman's correlation test to assess the correlation between age at diagnosis (measured here as age at blood draw) and the PRS among AMD cases. In Figure S4, we show a modest, yet significant, negative correlation between the variables (p=-0.18, p-value=0.0003, using the best LDpred2 PRS), suggesting that the PRS may be associated not only with disease status but also with age of onset.

Discussion

In this work, we studied the genetic basis of AMD in the Israeli populations. We confirmed that most of the known risk loci for AMD, as previously identified in a large international study, are also associated with AMD in Israel. This suggests that the genetic architecture of AMD is similar between the Israeli and other populations. We then performed a genome-wide association study in our cohort in an attempt to identify novel risk variants. As expected due to the small size of our cohort, no novel variants were detected at the genome-wide significance threshold. Setting a more relaxed threshold of 5·10⁻⁵, we identified four suggestive variants. One of these variants (rs1195500, in *FAM189A1*) replicated, after Bonferroni correction, in a small second set of cases and controls.

The evaluation of the AMD PRS in our Israeli cohort suggested multiple conclusions. First, the LDpred2 PRS had relatively high accuracy (AUC=0.82), significantly better compared to not including the PRSs (Figure 1). Second, with the simple clumping and thresholding approach, accuracy increased as more stringent p-value thresholds were used (Figure S3). This could indicate that AMD is not as polygenic as other diseases. Third, as expected^{26,27}, LDpred2 performed better than the C+T approach (Figure 2A). Finally, high AMD PRS in our study associated not only with disease risk, but also with a lower age of

onset (Figure S4), as seen for diseases in other domains^{28,29}. Prospective studies will be required to further validate this finding.

Our results for high predictive power of the AMD PRS are in line with previous studies ^{30,31} in individuals

of European ancestry. The transferability of the PRS to the Israeli population is perhaps expected given that the majority of our subjects had Ashkenazi Jewish ancestry, and given that PRSs for other diseases and traits were shown to have high accuracy in Ashkenazi Jews ^{32–35}. The transferability of PRSs into Ashkenazi Jews may be due to the high percentage of European ancestry in this population ⁷. It is also consistent with our replication of the known risk loci. Our sample size was too small to evaluate the PRS accuracy in other sub-populations, which could be the goal of future studies. Further improvement of the PRS may be achieved via denser genotyping or larger and more diverse imputation reference panels. Additionally, multiple methods can leverage even small samples from a target non-European population to improve a PRS constructed using large GWASs in Europeans ^{36,37}. However, such efforts will require additional samples for evaluation of the resulting PRSs.

Materials and Methods

Our discovery set consisted of 403 AMD cases and 256 controls (659 total) recruited at Hadassah Medical Center, as previously reported ³⁸. Our cases included both atrophic and neovascular (a more advanced) AMD. The subjects' mean age was 75.4 years (SD: 2.76, range: 60-97) and 44.6% were female. The criteria for inclusion of AMD patients were: age >60, AMD diagnosis according to AREDS (Age-Related Eye Disease Study) ³⁹, and choroidal neovascularization (CNV) and/or geographic atrophy. Diagnosis was also determined according to fluorescein angiogram and optical coherence tomography. Participants were included in all stages of AMD. We excluded individuals with other retinal diseases and individuals with other potential CNV causes such as myopia, trauma, or uveitis. Controls were over the age of 60 with a normal fundus examination and similar systemic exclusion criteria. The study was

193 approved by the institutional ethics committee. All subjects signed informed consent forms that 194 adhered to the tenets of the declaration of Helsinki. 195 We genotyped all subjects on the custom chip that was developed for the IAMDGC. Genotyping on this 196 chip was performed either via the IAMDGC (at the Center for Inherited Disease Research (Johns Hopkins, 197 USA)) or at the genomics core facility of the Technion (Israel), as previously described ³¹. The custom 198 chip, which was previously described, contains ≈250,000 tagging markers for imputation and ≈250,000 custom markers for AMD². 199 200 We imputed the genomes of our subjects with the following reference panels: the 1000 Genomes Project (n=2504) 40 and the Ashkenazi Genome Consortium (n=128) 6. This strategy was shown to have 201 the highest accuracy for imputing Ashkenazi genomes ⁴¹ and was applied here, given that 60% of our 202 203 subjects have Ashkenazi ancestry. Unfortunately, a reference panel for non-Ashkenazi Jews or for the non-Jewish populations of Israel does not yet exist. We phased our genomes using SHAPEIT 42,43 and 204 performed imputation using a standard protocol ^{43,44}. We describe next the post-imputation quality 205 control (QC) pipeline, as we previously developed ^{38,45}. 206 The chip was imputed to 37,126,112 variants. We performed QC according to standard protocols to remove low-quality variants and samples ⁴⁶. We excluded variants with imputation quality score R²<0.6, 208 209 variants with minor allele frequency <0.01, and variants in Hardy-Weinberg disequilibrium (PLINK 1.9 ^{47,48}). The sex of patients was confirmed using the sex-check option in PLINK. We excluded individuals 210 211 who were related, having PIHAT>0.3 in PLINK. We performed principal components analysis (PCA) in 212 PLINK and GCTA ⁴⁹ to account for population stratification; the first two principal components were used 213 as covariates in the association analysis (Figure S1). The final variant count after filtering was 5,353,842 214 variants in 403 AMD patients and 256 controls.

We performed the discovery GWAS on case-control status using logistic regression in PLINK. To account for population stratification, we used the first two principal components as covariates. The other covariates were age at blood draw and sex. We generated Manhattan and Q-Q plots with qqman. For genome-wide significance, we used a p-value threshold of 5·10⁻⁸. To detect suggestive associations, we used a threshold of 5·10⁻⁵. We computed the frequency of risk alleles (either in Europeans or in Ashkenazi Jews) using gnomAD (http://gnomad.broadinstitute.org/) and, if exonic, also in the Exome Variant server (http://evs.gs.washington.edu/EVS). Variants that were outside gene boundaries were reported to nearest gene. Variants contained within a gene were reported with that gene. To determine whether previously discovered associations replicate in our study, we considered variants within the 34 known loci that were identified in the IAMDGC 2016 GWAS ² (Table 5 in the IAMDGC GWAS paper). For each locus (LD block) we retained the variant with the lowest p-value. We considered a nominal significance level of P=0.05 or a Bonferroni corrected level of P=0.05/34=0.0015. To test for population-specific replication, we separately studied Ashkenazi Jews (AJ; 242 cases, 136 controls) and Arabs (36 cases and 30 controls). We identified AJ by self-report, requiring both parents to have AJ ancestry, and via their clustering in a principal components analysis with the Ashkenazi reference genomes (Figure S1). We identified Arab subjects based on self-report (36 cases and 30 controls). We considered all variants in linkage disequilibrium (LD; r²>0.05 in AJ, using hg19 linkage blocks as per the original Fritsche et al 2016 paper) to belong to the same locus. We note that 549/649 of our subjects were part of the original IAMDGC GWAS ² (out of a total of 33,976 individuals). Therefore, some degree of replication is expected just by virtue of this sample overlap. However, given that the Israeli samples were less than 2% of the total IAMDGC sample, the effect of the overlap is expected to be small. To replicate putative discoveries from the present study, we recruited additional 155 AMD cases and 69 controls (total 224) according to the same criteria as in the original discovery set. We used this

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

case/control sample to validate the suggestively associated variants from the discovery set. Four variants passed the 5·10⁻⁵ genome-wide threshold in the discovery set, after excluding variants in known AMD risk loci. We genotyped these four variants in our entire replication set using the KASP assay (LGC Group, Middlesex, UK) with custom primers. All heterozygotes were confirmed using Sanger sequencing (Macrogen, Seoul, Korea). We tested the association using EPACTS (https://genome.sph.umich.edu/wiki/EPACTS) and R using two tests. For each SNP, an allelic test compared the proportion of minor alleles between cases and controls. A genotypic test compared the proportion of homozygotes to the minor allele out of all homozygotes between cases and controls. To generate a polygenic risk score for AMD, we first performed quality control according to standard protocols. In parallel, we excluded the Israeli samples from the IAMDGC dataset and re-ran the GWAS analysis (remaining n=33,515; the "base" study). We used the resulting effect sizes to compute the PRS for individuals in the Israeli study (n=659; the "target" study). We removed variants with strandambiguous variants from the base study's summary statistics. Duplicated variants were removed from both studies, separately. Variants with mismatching alleles were also removed. This has left 4,070,992 overlapping variants between the two studies (directly genotyped or imputed). We generated polygenic risk scores using two approaches for variant selection: clumping and thresholding (C+T) and LDpred2. Briefly, in C+T, index variants are sequentially selected based on having the lowest p-value, and nearby variants in LD with the index variants are removed. Index variants with pvalue under a threshold are retained^{50,51}. We computed LD (r²) using PLINK and the target study. We set the clumping parameters to r²>0.5 and ±500 kb and used nine p-value thresholds: 5·10⁻⁸, and 10⁻⁷, 10⁻⁶, 10⁻⁵, 10⁻⁴, 0.001, 0.01, 0.1, and 1. The minimum p-value cutoff was set to match the IAMDGC genomewide significance threshold. LDpred2 is a Bayesian method for deriving polygenic scores based on summary statistics while explicitly accounting for LD. Briefly, causal effect sizes are assumed to be a mixture of a normal distribution and a

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

point mass at zero. Posterior mean effects are computed using Gibbs sampling based on the LD matrix and an estimate of the heritability 26,27 . We set the SNP heritability (h^2) to 0.47 based on a previous IAMDGC estimate³¹ and used five proportions of causal variants (p) spaced on a log scale: 10⁻⁵, 1.8·10⁻⁴, 0.0032, 0.056, and 1. We also included a third parameter of sparsity (true/false). The analysis was restricted to HapMap3 variants. The LD matrix was computed using the target study. We used the R package bigsnpr to compute the LD matrix and generate the grid of scores ²⁷. To avoid confounding by ancestry, in both methods we regressed the scores on the first two principal components and used the residuals as the scores in subsequent analyses. We used PLINK to calculate PRSs for each of the 659 subjects. Overall, we obtained nine C+T PRSs (nine p-value cutoffs) and ten LDpred2 PRSs, of which four were reported as valid by LDpred2 (p=0.056, sparse=FALSE; p=0.056, sparse=TRUE; p=1, sparse=FALSE; p=1, sparse=TRUE). To evaluate the accuracy of each score, we used logistic regression of the disease status on the PRS and the following covariates: age, sex, PC1, and PC2. We also included a logistic regression model based on covariates only. We measured the accuracy of each model using the area under the curve (AUC) of the receiver operator curves (ROC), computed using 5-fold cross validation. We used the R package pROC (https://cran.rproject.org/web/packages/pROC/pROC.pdf) to generate and analyze ROCs, AUCs, and AUC confidence intervals (ci.auc ()), and the R package caret (https://cran.rproject.org/web/packages/caret/vignettes/caret.html) for cross-validation. Individuals with missing age data were excluded from the analysis (four cases and five controls). We visually inspected the discriminatory power of the PRS using plots of the density of the PRS in cases and controls (using kernel density estimation), and the proportion of AMD cases across quintiles (fifths) of the PRS distribution. Both plots were generated with the R package ggplot2 (https://cran.rproject.org/web/packages/ggplot2/index.html). Finally, we computed Spearman's rank correlation coefficient to examine the association between the PRS and age at blood draw (as a proxy of the age at

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

diagnosis) among AMD cases. Plots were generated with R package *ggpubr* (https://cran.r-project.org/web/packages/ggpubr/index.html).

Author Contributions:

MG, DT, SC, IC, ER conceived and designed the work, MG, DT, ER, RS, RM designed and performed the experiments and data analysis, MG, DT, ER, RS, GB, LT, SK, SH-L, BR, RM, IC and SC provided data availability and data extraction and analysis, MG, DT, SC, IC wrote the manuscript, MG, DT, SC, IC, ER, RS, EH provided manuscript feedback, revision, and drafts.

Funding:

This work was supported by a grants from the Israel Science Foundation: 3485/19 to I.C. and S.C. The contribution of the International AMD Genomics Consortium (IAMDGC) was supported by a grant from NIH (R01 EY022310). Genotyping was supported by a contract (HHSN2682012000081) to the Center for Inherited Disease Research. MG is supported by a grant from the Bright Focus Foundation (M2021006F).

Ethical Approval:

The study was approved by the institutional ethics committee of Hadassah Medical Center. All subjects signed informed consent forms that adhered to the tenets of the declaration of Helsinki. The IAMDGC study participants were previously ascertained by IAMDGC cohorts as described in Fritsche et al, 2016, Nature Genetics. All participants provided informed consent, and the study was approved by institutional review boards as previously described.

Conflict of Interest Statement

S.C. is a paid consultant to MyHeritage. All other authors have no competing interests to disclose.

Data Availability:

309 The full IAMDGC dataset values can be accessed at: http://amdgenetics.org/including the entire 310 IAMDGC and the Jerusalem dataset specifically. In addition, the GWAS summary statistics and code 311 utilized in this manuscript can be found by contacting the corresponding author via reasonable request. 312 The Related Manuscript Variant supplementary file contains all nomenclature for HGVS for all variants. 313 **References:** 314 DeAngelis MM, Owen LA, Morrison MA, et al. Genetics of age-related macular degeneration 1. (AMD). Hum Mol Genet. 2017;26(R1):R45-R50. doi:10.1093/hmg/ddx228 315 2. 316 Fritsche LGLG, Igl W, Bailey JNCJNC, et al. A large genome-wide association study of age-related 317 macular degeneration highlights contributions of rare and common variants. Nat Genet. 318 2016;48(2):134-143. doi:10.1038/ng.3448 319 3. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-320 related macular degeneration. *Science* (80-). 2005;308(5720):419-421. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list 321 322 _uids=15761120. 323 4. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science (80-). 2005;308(5720):385-389. 324 325 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list 326 _uids=15761122. 327 5. Behar DM, Yunusbayev B, Metspalu M, et al. The genome-wide structure of the Jewish people. Nature. 2010;466(7303):238-242. doi:10.1038/nature09103 328 329 6. Carmi S, Hui KY, Kochav E, et al. Sequencing an Ashkenazi reference panel supports population-

targeted personal genomics and illuminates Jewish and European origins. Nat Commun.

2014;5:4835. doi:10.1038/ncomms5835

330

332	7.	Waldman S, Backenroth D, Harney É, et al. Genome-wide data from medieval German Jews show
333		that the Ashkenazi founder event pre-dated the 14(th) century. Cell. 2022;185(25):4703-
334		4716.e16. doi:10.1016/j.cell.2022.11.002
335	8.	Agranat-Tamir L, Waldman S, Martin MAS, et al. The Genomic History of the Bronze Age
336		Southern Levant. Cell. 2020;181(5):1146-1157.e11. doi:10.1016/j.cell.2020.04.024
337	9.	Granot-Hershkovitz E, Karasik D, Friedlander Y, et al. A study of Kibbutzim in Israel reveals risk
338		factors for cardiometabolic traits and subtle population structure. Eur J Hum Genet.
339		2018;26(12):1848-1858. doi:10.1038/s41431-018-0230-3
340	10.	Zidan J, Ben-Avraham D, Carmi S, Maray T, Friedman E, Atzmon G. Genotyping of geographically
341		diverse Druze trios reveals substructure and a recent bottleneck. Eur J Hum Genet.
342		2014;8(February):1093-1099. doi:10.1038/ejhg.2014.218
343	11.	Zeggini E. Using genetically isolated populations to understand the genomic basis of disease.
344		Genome Med. 2014;6(10):83. doi:10.1186/s13073-014-0083-5
345	12.	Zelinger L, Banin E, Obolensky A, et al. A missense mutation in DHDDS, encoding dehydrodolichyl
346		diphosphate synthase, is associated with autosomal-recessive retinitis pigmentosa in ashkenazi
347		jews. Am J Hum Genet. 2011;88(2):207-215. doi:10.1016/j.ajhg.2011.01.002
348	13.	Zlotogora J, Chemke J. Medical genetics in Israel. Eur J Hum Genet. 1995;3(3):147-154.
349		http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list
350		_uids=7583040.
351	14.	Beryozkin A, Shevah E, Kimchi A, et al. Whole Exome Sequencing Reveals Mutations in Known
352		Retinal Disease Genes in 33 out of 68 Israeli Families with Inherited Retinopathies. Sci Rep.
353		2015;5. doi:10.1038/srep13187
354	15.	Chowers I, Cohen Y, Goldenberg-Cohen N, et al. Association of complement factor H Y402H

355		polymorphism with phenotype of neovascular age related macular degeneration in Israel. <i>Mol</i>
356		Vis. 2008;14:1829-1834.
357		http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list
358		_uids=18852870.
359	16.	Chowers I, Meir T, Lederman M, et al. Sequence variants in HTRA1 and LOC387715/ARMS2 and
360		phenotype and response to photodynamic therapy in neovascular age-related macular
361		degeneration in populations from Israel. Mol Vis. 2008;14:2263-2271.
362		http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list
363		_uids=19065273.
364	17.	Asleh SAA, Lederman M, Weinstein O, et al. Lack of association between the C2 allele of
365		transferrin and age-related macular degeneration in the Israeli population. Ophthalmic Genet.
366		2009;30(4):161-164. doi:10.3109/13816810903147998 [pii] 10.3109/13816810903147998
367	18.	Babb de Villiers C, Kroese M, Moorthie S. Understanding polygenic models, their development
368		and the potential application of polygenic scores in healthcare. J Med Genet. 2020;57(11):725-
369		732. doi:10.1136/jmedgenet-2019-106763
370	19.	Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat
371		Rev Genet. 2018. doi:10.1038/s41576-018-0018-x
372	20.	Khera A V., Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases
373		identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018.
374		doi:10.1038/s41588-018-0183-z
375	21.	Heesterbeek TJ, de Jong EK, Acar IE, et al. Genetic risk score has added value over initial clinical
376		grading stage in predicting disease progression in age-related macular degeneration. Sci Rep.
377		2019;9(1):6611. doi:10.1038/s41598-019-43144-3

378	22.	Colijn JM, Meester-Smoor M, Verzijden T, et al. Genetic Risk, Lifestyle, and Age-Related Macular
379		Degeneration in Europe: The EYE-RISK Consortium. <i>Ophthalmology</i> . 2021;128(7):1039-1049.
380		doi:10.1016/j.ophtha.2020.11.024
381	23.	Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic
382		risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584-591.
383		doi:10.1038/s41588-019-0379-x
384	24.	Duncan L, Shen H, Gelaye B, et al. Analysis of polygenic risk score usage and performance in
385		diverse human populations. Nat Commun. 2019;10(1):3328. doi:10.1038/s41467-019-11112-0
386	25.	Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations
387		using PolyPhen-2. Curr Protoc Hum Genet. 2013;(SUPPL.76). doi:10.1002/0471142905.hg0720s76
388	26.	Vilhjálmsson BJ, Yang J, Finucane HK, et al. Modeling Linkage Disequilibrium Increases Accuracy
389		of Polygenic Risk Scores. <i>Am J Hum Genet</i> . 2015;97(4):576-592. doi:10.1016/j.ajhg.2015.09.001
390	27.	Privé F, Arbel J, Vilhjálmsson BJ. LDpred2: better, faster, stronger. Bioinformatics. 2020;36(22-
391		23):5424-5431. doi:10.1093/bioinformatics/btaa1029
392	28.	Thomas M, Sakoda LC, Hoffmeister M, et al. Genome-wide Modeling of Polygenic Risk Score in
393		Colorectal Cancer Risk. Am J Hum Genet. 2020;107(3):432-444. doi:10.1016/j.ajhg.2020.07.006
394	29.	Vaura F, Kauko A, Suvila K, et al. Polygenic Risk Scores Predict Hypertension Onset and
395		Cardiovascular Risk. <i>Hypertens (Dallas, Tex 1979)</i> . 2021;77(4):1119-1127.
396		doi:10.1161/HYPERTENSIONAHA.120.16471
397	30.	Qassim A, Souzeau E, Hollitt G, Hassall MM, Siggs OM, Craig JE. Risk Stratification and Clinical
398		Utility of Polygenic Risk Scores in Ophthalmology. Transl Vis Sci Technol. 2021;10(6):14.

doi:10.1167/tvst.10.6.14

- 400 31. Fritsche LG, Igl W, Bailey JNC, et al. A large genome-wide association study of age-related
- 401 macular degeneration highlights contributions of rare and common variants. *Nat Genet*.
- 402 2016;48(2):134-143. doi:10.1038/ng.3448
- 403 32. Gettler K, Levantovsky R, Moscati A, et al. Common and Rare Variant Prediction and Penetrance
- 404 of IBD in a Large, Multi-ethnic, Health System-based Biobank Cohort. *Gastroenterology*.
- 405 2021;160(5):1546-1557. doi:10.1053/j.gastro.2020.12.034
- 406 33. Belbin GM, Cullina S, Wenric S, et al. Toward a fine-scale population health monitoring system.
- 407 *Cell.* 2021;184(8):2068-2083.e11. doi:10.1016/j.cell.2021.03.034
- 408 34. Fahed AC, Aragam KG, Hindy G, et al. Transethnic Transferability of a Genome-Wide Polygenic
- 409 Score for Coronary Artery Disease. *Circ Genomic Precis Med*. 2021;14(1):e003092.
- 410 doi:10.1161/CIRCGEN.120.003092
- 411 35. Privé F, Aschard H, Carmi S, et al. Portability of 245 polygenic scores when derived from the UK
- 412 Biobank and applied to 9 ancestry groups from the same cohort. *Am J Hum Genet*.
- 413 2022;109(1):12-23. doi:10.1016/j.ajhg.2021.11.008
- 414 36. Cai M, Xiao J, Zhang S, et al. A unified framework for cross-population trait prediction by
- leveraging the genetic correlation of polygenic traits. *Am J Hum Genet*. 2021;108(4):632-655.
- 416 doi:10.1016/j.ajhg.2021.03.002
- 417 37. Kachuri L, Chatterjee N, Hirbo J, et al. Principles and methods for transferring polygenic risk
- scores across global populations. *Nat Rev Genet*. August 2023. doi:10.1038/s41576-023-00637-2
- 419 38. Lorés-Motta L, Riaz M, Grunin M, et al. Association of genetic variants with response to anti-
- 420 vascular endothelial growth factor therapy in age-related macular degeneration. JAMA
- 421 *Ophthalmol.* 2018. doi:10.1001/jamaophthalmol.2018.2019
- 422 39. Age-Related Eye Disease Study Research G. The Age-Related Eye Disease Study (AREDS): design

423 implications. AREDS report no. 1. Control Clin Trials. 1999;20(6):573-600. 424 http://www.ncbi.nlm.nih.gov/pubmed/10588299. 425 40. The 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature*. 426 2015;526(7571):68-74. doi:10.1038/nature15393 427 41. Lencz T, Yu J, Palmer C, et al. High-depth whole genome sequencing of an Ashkenazi Jewish 428 reference panel: enhancing sensitivity, accuracy, and imputation. Hum Genet. 2018;137(4):343-355. doi:10.1007/s00439-018-1886-z 429 430 42. Delaneau O, Marchini J, Zagury J-F. A linear complexity phasing method for thousands of 431 genomes. Nat Methods. 2012;9(2):179-181. doi:10.1038/nmeth.1785 432 43. Delaneau O, Zagury J-F, Marchini J. Improved whole-chromosome phasing for disease and 433 population genetic studies. Nat Methods. 2013;10(1):5-6. doi:10.1038/nmeth.2307 van Leeuwen EM, Kanterakis A, Deelen P, et al. Population-specific genotype imputations using 434 44. minimac or IMPUTE2. Nat Protoc. 2015;10(9):1285-1296. doi:10.1038/nprot.2015.077 435 436 45. Grunin M, Beykin G, Rahmani E, et al. Association of a variant in VWA3A with response to anti-437 vascular endothelial growth factor treatment in neovascular AMD. Investig Ophthalmol Vis Sci. 2020. doi:10.1167/iovs.61.2.48 438 439 46. Anderson CA, Pettersson FHFHFH, Clarke GMGMGM, Cardon LR, Morris AP, Zondervan KT. Data 440 quality control in genetic case-control association studies. Nat Protoc. 2010;5(9):1564-1573. doi:10.1038/nprot.2010.116 441 Chang CC, Chow CC, Tellier LC a. M, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: 442 47. 443 rising to the challenge of larger and richer datasets. 2014:1-22.

http://arxiv.org/abs/1410.4803v1.

Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for whole-genome association and 445 48. 446 population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-575. doi:10.1086/519795 447 49. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: A tool for genome-wide complex trait analysis. 448 *Am J Hum Genet*. 2011;88(1):76-82. doi:10.1016/j.ajhg.2010.11.011 449 50. Privé F, Vilhjálmsson BJ, Aschard H, Blum MGB. Making the Most of Clumping and Thresholding 450 for Polygenic Scores. Am J Hum Genet. 2019;105(6):1213-1221. doi:https://doi.org/10.1016/j.ajhg.2019.11.001 451 452 51. Choi SW, Mak TS-H, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat 453 *Protoc.* 2020;15(9):2759-2772. doi:10.1038/s41596-020-0353-1 454 **Figures Legends:** 455 Figure 1. Prediction accuracy of selected PRS models. We show the ROC curve for the following AMD prediction models: the top C+T PRS (Figure S3) + covariates (age, sex, PC1, and PC2); the top LDpred2 456 457 PRS + covariates; and a covariates-only model. The C+T PRS parameters were $r^2 > 0.5$ and $P < 5.10^{-8}$, and 458 the LDpred2 PRS parameters were p=0.056 and sparse=TRUE. The AUC estimates (after cross-validation) 459 are indicated on top of the plot. 460 Figure 2. Comparing the PRS between cases and controls. (A) The density of the top LDpred2 PRS (after 461 regressing out the first two principal components) in AMD cases and controls in our study (n=403 and 462 259, respectively). (B) The proportion of AMD cases in our study by PRS quintiles. We again used the top 463 LDpred2 PRS. 464 **Tables Legends:** 465 Table 1. Statistics for the association of SNPs with AMD status in our Israeli discovery cohort. Genomic 466 coordinates are in hg19. The gene is the nearest to the SNP. Allele frequencies were computed in

gnomAD, for either non-Finnish Europeans (NFE) or Ashkenazi Jews (AJ). The first four rows provide

details on four SNPs associated with AMD in our discovery cohort with p-value $<5\cdot10^{-5}$. The last row presents details on the top-associated SNP in the AJ subset of our cohort.

Table 1:

SNP ID	Genomic Position (hg19)	Gene		P-value (entire	Odds ratio (95% confidence interval) Entire cohort, AJ subset	frequency	frequency (gnomAD	leave one	Replication P- value Genotype (Fisher's exact)
rs12701455	chr7:1055409	C7orf50		5.05x10 ⁻⁶	0.5 (0.26-94)	0.147/0.251	0.309/0.212	0.78	0.028
rs116928937	chr15:65677446	IGDCC4	Missense	3.73x10 ⁻⁶	0.13(0.02-0.83), 0.07	0.008/0.055	0.0185/0.0064	0.89	1
rs1506825	chr16:76483019	CNTNAP4		6.91x10 ⁻⁶	0.57(0.34-0.96)	0.4373/0.5703	0.455/0.469	0.04	0.85
rs1195500	chr15:29687047	FAM189A1		2.265x10 ⁻⁵	0.51(0.27-0.96), 0.37	0.129/0.227	0.26/0.15	0.27	0.00001
rs11689931				3.19x10 ⁻⁶ for					
(AJ specific)	chr2:206440979	PARD3B		AJ	0.07	0.20/0.37 in AJ	0.301/0.306		Was not tested

Figure 1




Figure 2A





Figure 2B



488	Genome-wide association study and genomic risk prediction of age-related
489	macular degeneration in Israel
490	Supplementary Material
491	Related Manuscript Variant File: Contains nomenclature for every variant listed in this paper according
492	to HGVS, checked with Mutalyzer.
493	Supplementary Figures Legends
494	Figure S1. A PCA plot of the entire discovery cohort. Each symbol represents a single individual.
495	Individuals are color coded based on their self-reported ancestry: Ashkenazi (n=378), North African
496	Sephardi, Turkey, and other Sephardi (n=215), Arab (n=66), and Israel general (n=10). The shape of each
497	symbol corresponds to the AMD PRS quintile (see legend).
498	Figure S2. A Manhattan plot for the GWAS of AMD in the Israeli discovery cohort (n=659). The X axis
499	indicates chromosomal position, and the Y axis indicates significance, as measured by $-log_{10}P$.
500	Figure S3. Accuracy of logistic regression models for predicting AMD disease status using
501	clumping+thresholding (C+T) PRSs. The models also included the following covariates: age, sex, PC1,
502	and PC2. Each curve corresponds to one of nine p-value cutoffs (see legend). The AUC values (after
503	cross-validation) are presented in the legend. CI: confidence interval. Prediction accuracy increased as
504	the p-value threshold decreased.
505	Figure S4. A scatter plot of age at blood draw and PRS among AMD cases (n=399). We used the best-
506	performing LDpred2 PRS. The PRS was adjusted for PC1 and PC2 to account for confounding by ancestry
507	The presented age is a proxy for the age at diagnosis. The linear regression parameters are indicated (r=
508	0.18, P=0.0003). The regression line is also shown, along with the 95% confidence interval (gray band).
509	Supplementary Tables Legends

Supplementary Table 1: Replication cohort results (n=224) for validation of four top associated SNPs from the AMD GWAS in the Israeli population. Genotype and allelic p-values according to Fisher's exact test are given. The bold bars separate the four SNPs tested for validation. The table provides their genotypes in the replication cohort tested and the p-values.

Supplementary Table 2. Association statistics of 27 variants in 11 known AMD risk loci that replicated in the Israeli discovery set after Bonferroni correction (threshold 0.05/34=0.0015). For each variant, we provide the gene, chromosome (Chr), basepair (BP), odds ratio (OR), 95 percent confidence interval (95% CI) and p-value (P). The variants are sorted by their p-value.

Supplementary Table 3. Association statistics of variants in known AMD risk loci that were nominally associated with AMD in the Israeli discovery set (P<0.05, 31/34 loci).

Supplementary Table 4. Association statistics of variants in known AMD risk loci in the Ashkenazi subpopulation (P<1x10-4). The data is reported as in Supplementary Table 3.

Supplementary Table 5 Association statistics of variants in known AMD risk loci in the Arab subpopulation (P<1x10-4). The data is reported as in Supplementary Table 3.

Figure S1:




Figure S2:




Figure S3:





Figure S4:



Supplementary Tables

Supplementary Table 1:

rs12701455					
Chromosome 7- BP	Homozygote		Homozygote	p-value	p-value
1055409	Major	Heterozygote	Minor	(Genotype)	(Allele)
AMD	40	1	3	0.0287	0.53
Control	35	6	0		

rs116928937					
Chromosome 15 – BP	Homozygote		Homozygote	p-value	p-value
65677446	Major	Heterozygote	Minor	(Genotype)	(Allele)
AMD	108	4	0	0.92	1
Control	73	2	0		
rs1506825					
Chromosome 16 – BP	Homozygote		Homozygote	p-value	p-value
76483019	Major	Heterozygote	Minor	(Genotype)	(Allele)
AMD	59	66	38	0.85	0.34
Control	25	29	20		
rs1195500					
Chromosome 16 – BP	Homozygote		Homozygote	p-value	p-value
29687047	Major	Heterozygote	Minor	(Genotype)	(Allele)
AMD	110	37	8	<0.0001	<0.0001
Control	31	24	14		

Supplementary Table 2:

	Gene	Chr	ВР	OR	95%CI	Р

					[0.25-	
1	CFH	1	196695161	0.4687	0.85]	1.56E-09
					[1.16-	
2	ARMS2	10	124214448	2.071	3.84]	3.424E-09
					[1.15-	
3	HTRA1	10	124221270	2.061	3.79]	5.077E-09
					[0.29-	
4	CFHR5	1	196978615	0.5161	0.89]	5.195E-08
					[1.11-	
5	CFHR2	1	196927791	1.894	3.39]	1.163E-07
					[0.21-	
6	CFHR4	1	196870299	0.436	0.96]	0.00000762
					[0.33-	
7	KCNT2	1	196406715	0.5845	0.96]	0.00001443
					[1.03-	
8	F13B	1	197012111	1.7	2.83]	0.00001487
					[0.13-	
9	SYN3	22	33047598	0.3696	0.97]	0.00005685
					[1.01-	
10	ASPM	1	197094030	1.616	2.62]	0.0000688

					[0.19-	
11	ZBTB41	1	197132378	0.4372	0.99]	0.0000732
					[0.39-	
12	PLEKHA1	10	124148167	0.6403	0.98]	0.0001034
					[0.31-	
13	VPS29	12	110935268	0.5591	1.01]	0.000218
14	CRB1	1	197199434	1.568	[0.99-2.5]	0.0002242
					[0.24-	
15	PPTC7	12	110994068	0.5699	1.01]	0.0002391
					[0.98-	
16	ZNF557	19	7083629	1.576	2.51]	0.0002624
					[0.26-	
17	HVCN1	12	111099721	0.5184	1.03]	0.0004554
					[0.97-	
18	MICALL1	22	38318897	1.48	2.25]	0.0007491
					[0.17-	
19	SMC5	9	72920724	0.427	1.06]	0.0008093
					[0.34-	
20	PPP1CC	12	111160003	0.5937	1.04]	0.0008394

					[0.32-	
21	TCTN1	12	111081197	0.5847	1.04]	0.0008647
					[0.22-	
22	HLA-B	6	31324864	0.4779	1.06]	0.0008669
					[0.29-	
23	RAD9B	12	110948906	0.5532	1.0504]	0.001058
					[0.97-	
24	EIF3L	22	38273303	1.476	2.25]	0.001161
					[0.46-	
25	TTC23L	5	34840841	0.6909	1.033]	0.001183
					[0.02-	
26	ACHE	7	100491753	0.1589	1.18]	0.001267
					[0.44-	
27	KIAA0100	17	26956537	0.6755	1.04]	0.001267

Supplementary Table 3:

AMD Locus According to Fritsche et al 2016	Approved Symbol (HGNC)	P-value
1	CFH	1.56E-09
18	ARMS2	3.424E-09
18	HTRA1	5.077E-09
1	CFHR5	5.195E-08

1	CFHR2	1.163E-07
1	CFHR4	0.00000762
1	KCNT2	0.00001443
1	F13B	0.00001487
33	SYN3	0.00005685
1	ASPM	0.0000688
1	ZBTB41	0.0000732
18	PLEKHA1	0.0001034
1	CRB1	0.0001282
20	PPTC7	0.0001725
28	ZNF557	0.0001836
20	VPS29	0.000218
20	HVCN1	0.0004554
34	MICALL1	0.0007491
14	SMC5	0.0008093
20	PPP1CC	0.0008394
20	TCTN1	0.0008647
8	HLA-B	0.0008669
20	RAD9B	0.001058
34	EIF3L	0.001161
7	TTC23L	0.001183
11	ACHE	0.001267
26	KIAA0100	0.001267
3	ADAMTS9-AS2	0.001549
20	FAM216A	0.001563
8	VARS	0.001596
8	C6orf48	0.00162
10	LHFPL3	0.001763
18	TACC2	0.002007
34	GCAT	0.002065
7	RAI14	0.002168
8	PRRC2A	0.002247
8	LSM2	0.002253
27	ACTG1	0.002291
8	SLC44A4	0.002362
30	TOMM40	0.002687
5	EGF	0.002703
22	ZFP36L1	0.002801
8	MSH5	0.002847
		•

8	MSH5-SAPCD1	0.002847
7	LMBRD2	0.002997
17	KIAA1217	0.00307
8	BAG6	0.003264
8	ABHD16A	0.003366
10	SRPK2	0.003392
8	C6orf47	0.003486
8	GPANK1	0.003486
8	LY6G5C	0.003486
8	CSNK2B	0.003674
31	SLC12A5	0.003686
23	SLTM	0.00382
8	SAPCD1	0.003898
33	TIMP3	0.003935
5	COL25A1	0.004167
34	BAIAP2L2	0.004208
19	DGKA	0.004239
8	EHMT2	0.004284
8	VWA7	0.004415
28	ZNRF4	0.004423
20	DTX1	0.004452
8	C2	0.004495
28	RFX2	0.004542
12	TNFRSF10B	0.004838
28	INSR	0.004913
5	ELOVL6	0.004992
30	APOC1	0.005035
19	WIBG	0.005741
8	LY6G6F	0.005813
25	GABARAPL2	0.006067
8	HCG26	0.006204
30	PVRL2	0.006553
2	RHBDD1	0.006662
28	ACER1	0.006821
25	ADAT1	0.006832
10	ATXN7L1	0.007322
8	NCR3	0.00746
31	CDH22	0.007473
26	PIGS	0.007713

28	DUS3L	0.007766
34	H1F0	0.007772
34	C22orf23	0.007828
8	ATP6V1G2	0.008046
8	ATP6V1G2-DDX39B	0.008046
8	NFKBIL1	0.008046
21	TEX26	0.008121
11	GIGYF1	0.008345
25	CHST5	0.008811
4	COL8A1	0.008929
4	MIR548G	0.008929
25	KARS	0.008961
30	GEMIN7	0.009067
23	AQP9	0.009112
24	DOK4	0.009633
8	MICA	0.009687
29	SBNO2	0.009692
34	SOX10	0.009929
12	RHOBTB2	0.009956
29	HMHA1	0.009991
26	NEK8	0.009999
9	CAPN11	0.01005
7	DNAJC21	0.01008
26	SDF2	0.01016
28	PRR22	0.0104
34	POLR2F	0.0105
30	ZNF285	0.01068
2	COL4A4	0.01086
3	PRICKLE2	0.01118
28	CATSPERD	0.01123
19	CD63	0.01133
8	TCF19	0.01249
8	HLA-DQB2	0.01254
8	PSORS1C1	0.01291
23	FAM63B	0.01298
2	COL4A3	0.01309
14	TRPM3	0.0132
8	AIF1	0.01348
3	ADAMTS9	0.0135
		•

24	CPNE2	0.01373
7	SKP2	0.01374
25	CTRB1	0.01374
25	TMEM231	0.01388
22	RAD51B	0.01394
8	SKIV2L	0.01439
32	PCK1	0.01459
26	SUPT6H	0.01433
30	KLC3	0.01474
4	CMSS1	0.01478
4	FILIP1L	0.01478
20	OAS1	0.01473
8	BTNL2	0.01493
20	CCDC63	0.01593
2	AGFG1	0.01593
28	SAFB	0.01649
8	C6orf10	0.01673
11	AZGP1	0.01673
8	HCG23	0.01694
32	APCDD1L	0.01701
24	SLC12A3	0.01701
8	ABCF1	0.01709
19	PAN2	0.01727
10	PUS7	0.01732
5	CCDC109B	0.01772
29	TMEM259	0.01763
11	EPO	0.01823
23	LIPC	0.01831
30	CLASRP	0.01835
6	DAB2	0.01893
21	B3GALTL	0.01913
21	TEX26-AS1	0.01938
19	CS	0.01939
8	TAP2	0.01974
30	PVR	0.01982
17	GPR158	0.01988
3	MIR548A2	0.01991
23	ADAM10	0.01999
11	ZNF3	İ
11	ZNF3	0.02024

8 CCHCR1 0.0207 25 BCAR1 0.0212 25 TERF2IP 0.0214 8 MRP518B 0.0214 29 GRIN3B 0.0216 30 ERCC2 0.0219 10 KMT2E-AS1 0.022 27 ASPSCR1 0.0224 29 C19orf26 0.0224 29 C19orf26 0.0224 20 CUX2 0.0226 20 ABCA7 0.0231 21 MKM72E 0.0221 22 ACTN1 0.0231 23 NLK <t< th=""><th></th><th></th><th></th></t<>			
25 BCAR1 0.0212: 25 TERF2IP 0.0214: 8 MRPS18B 0.02146 29 GRIN3B 0.0216 30 ERCC2 0.0219: 10 KMT2E-AS1 0.022: 27 ASPSCR1 0.0224: 29 C19orf26 0.0224: 25 CTRB2 0.0226: 8 CDSN 0.0228: 29 ABCA7 0.0231: 10 KMT2E 0.0231: 10 KMT2E 0.0231: 22 ACTN1 0.0237: 28 C3 0.0237: 28 C3 0.0237: 28 C3 0.0237: 29 PRSS57 0.0260: 30 RTCB 0.0256: 31 PCIF1 0.0250: 31 PCIF1 0.0256: 31 PCIF1 0.0256: 31 PCIF1 0.0256: 30 CBLC 0.0266: 29 CNN2 0.0266: 29 CNN2 0.0256: 30 CBLC 0.0266: 31 CBLC 0.0267: 32 CNN2 0.0266: 32 CNN2 0.0267: 34 CX3CL1 0.0269: 35 CAPSL 0.0266: 36 CAPSL 0.0266: 37 CAPSL 0.0267: 38 CAPSL 0.0266: 39 CNN2 0.0267: 30 CAPSL 0.0266: 30 CAPSL 0.0266: 31 CAPSL 0.0266: 32 CAPSL 0.0266: 33 CAPSL 0.0266: 34 CX3CL1 0.0269: 35 CAPSL 0.0276:	18	DMBT1	0.02062
25 TERF2IP 0.0214* 8 MRPS18B 0.0214* 29 GRIN3B 0.0216* 30 ERCC2 0.0219* 10 KMT2E-AS1 0.022* 27 ASPSCR1 0.0222* 29 C19orf26 0.0224* 25 CTRB2 0.0226* 20 CUX2 0.0226* 8 CDSN 0.0228* 29 ABCA7 0.0231* 10 KMT2E 0.0231* 22 ACTN1 0.0237* 28 C3 0.0237* 26 NLK 0.0240* 19 RNF41 0.0240* 19 RNF41 0.0241* 8 LONP1 0.0250* 29 PRSS57 0.0250* 29 PRSS57 0.0250* 27 HGS 0.0254* 31 PCIF1 0.0254* 31 PCIF1 0.0254* 31 <td< td=""><td>8</td><td>CCHCR1</td><td>0.02071</td></td<>	8	CCHCR1	0.02071
8 MRPS18B 0.02146 29 GRIN3B 0.0216 30 ERCC2 0.0219 10 KMT2E-AS1 0.022 27 ASPSCR1 0.0224 29 C19orf26 0.0224 25 CTRB2 0.0226 20 CUX2 0.0226 8 CDSN 0.0228 29 ABCA7 0.0231 10 KMT2E 0.0231 22 ACTN1 0.0237 28 C3 0.0237 26 NLK 0.0240 19 RNF41 0.0241 8 MICB 0.0241 28 LONP1 0.0250 29 PRSS57 0.0250 10 LINC01004 0.0253 27 HGS 0.0254 33 RTCB 0.0254 31 PCIF1 0.0254 31 PCIF1 0.0255 30 CBLC	25	BCAR1	0.02125
29 GRIN3B 0.0216 30 ERCC2 0.0219 10 KMT2E-AS1 0.022 27 ASPSCR1 0.02224 29 C19orf26 0.0224 25 CTRB2 0.0226 8 CDSN 0.0228 29 ABCA7 0.0231 10 KMT2E 0.0231 22 ACTN1 0.0237 28 C3 0.0237 26 NLK 0.0240 19 RNF41 0.0241 8 MICB 0.0244 28 LONP1 0.0250 29 PRSS57 0.0250 10 LINCO1004 0.0253 27 HGS 0.0254 33 RTCB 0.0254 31 PCIF1 0.0254 31 PCIF1 0.0254 33 RTCB 0.0265 4 NOTCH4 0.0259 8 NOTCH4	25	TERF2IP	0.02145
SOUTH SOUT	8	MRPS18B	0.02146
10	29	GRIN3B	0.02167
27 ASPSCR1 0.02223 29 C19orf26 0.0224 25 CTRB2 0.0226 20 CUX2 0.0226 8 CDSN 0.0228 29 ABCA7 0.0231 10 KMT2E 0.0231 22 ACTN1 0.0237 28 C3 0.0237 26 NLK 0.0240 19 RNF41 0.0241 8 MICB 0.0241 8 MICB 0.0244 28 LONP1 0.0250 29 PRSS57 0.0250 29 PRSS57 0.0250 27 HGS 0.0254 33 RTCB 0.0254 31 PCIF1 0.0254 31 PCIF1 0.0254 31 PCIF1 0.0259 30 CBLC 0.0261 25 CHST6 0.0266 25 CHST6 0.0267 <td>30</td> <td>ERCC2</td> <td>0.02194</td>	30	ERCC2	0.02194
29 C19orf26 0.0224: 25 CTRB2 0.0226: 20 CUX2 0.0226: 8 CDSN 0.0231: 29 ABCAT 0.0231: 10 KMT2E 0.0237: 28 C3 0.0237: 26 NLK 0.0240: 19 RNF41 0.0241: 8 MICB 0.0244: 28 LONP1 0.0250: 29 PRSS57 0.0250: 29 PRSS57 0.0250: 27 HGS 0.0254: 33 RTCB 0.0254: 31 PCIF1 0.0254: 31 PCIF1 0.0259: 30 CBLC 0.0261: 25 CHST6 0.026: 6 FYB 0.0265: 29 CNN2 0.0267: 27 SLC25A10 0.0267: 24 CX3CL1 0.0269: 7 CAPSL	10	KMT2E-AS1	0.0221
25	27	ASPSCR1	0.02225
20 CUX2 0.02268 8 CDSN 0.0228 29 ABCA7 0.0231 10 KMT2E 0.0237 22 ACTN1 0.0237 26 NLK 0.0240 19 RNF41 0.0241 8 MICB 0.0244 28 LONP1 0.0250 29 PRSS57 0.0250 29 PRSS57 0.0250 10 LINCO1004 0.0253 27 HGS 0.0254 33 RTCB 0.0254 31 PCIF1 0.0254 31 PCIF1 0.0254 31 PCIF1 0.0255 7 PRLR 0.0259 8 NOTCH4 0.0259 30 CBLC 0.0261 25 CHST6 0.0266 6 FYB 0.0265 29 CNN2 0.0267 27 SLC25A10 0.0269 <td>29</td> <td>C19orf26</td> <td>0.02243</td>	29	C19orf26	0.02243
8 CDSN 0.02283 29 ABCA7 0.0231 10 KMT2E 0.0231 22 ACTN1 0.0237 28 C3 0.0237 26 NLK 0.0240 19 RNF41 0.0241 8 MICB 0.0244 28 LONP1 0.0250 29 PRSS57 0.0250 10 LINC01004 0.0253 27 HGS 0.0254 33 RTCB 0.0254 31 PCIF1 0.0254 31 PCIF1 0.0256 7 PRLR 0.0259 8 NOTCH4 0.0259 30 CBLC 0.0261 25 CHST6 0.0265 29 CNN2 0.0267 27 SLC25A10 0.0269 7 CAPSL 0.0269 7 CAPSL 0.0276	25	CTRB2	0.02263
29 ABCA7 0.0231 10 KMT2E 0.0231 22 ACTN1 0.0237 28 C3 0.0237 26 NLK 0.0240 19 RNF41 0.0241 8 MICB 0.0244 28 LONP1 0.0250 29 PRSS57 0.0250 20 LINC01004 0.0253 27 HGS 0.0254 33 RTCB 0.0254 31 PCIF1 0.0254 31 PCIF1 0.0256 7 PRLR 0.0259 8 NOTCH4 0.0259 30 CBLC 0.0261 25 CHST6 0.026 6 FYB 0.0265 29 CNN2 0.0267 27 SLC25A10 0.0269 7 CAPSL 0.0276	20	CUX2	0.02269
29 ABCA7 0.0231 10 KMT2E 0.0231 22 ACTN1 0.0237 28 C3 0.0237 26 NLK 0.0240 19 RNF41 0.0240 8 MICB 0.0244 28 LONP1 0.0250 29 PRSS57 0.0250 10 LINC01004 0.0253 27 HGS 0.0254 33 RTCB 0.0254 31 PCIF1 0.0254 31 PCIF1 0.0255 7 PRLR 0.0259 8 NOTCH4 0.0259 30 CBLC 0.0261 25 CHST6 0.026 6 FYB 0.0265 29 CNN2 0.0267 27 SLC25A10 0.0269 7 CAPSL 0.0276	8	CDSN	0.02282
10 KMT2E 0.02314 22 ACTN1 0.02375 28 C3 0.0237 26 NLK 0.02405 19 RNF41 0.02405 19 RNF41 0.02405 28 LONP1 0.02505 29 PRSS57 0.02507 10 LINC01004 0.02536 27 HGS 0.02547 33 RTCB 0.02547 31 AZGP1P1 0.02547 31 PCIF1 0.02597 30 CBLC 0.02617 25 CHST6 0.02617 25 CHST6 0.02657 29 CNN2 0.02674 27 SLC25A10 0.02674 24 CX3CL1 0.02699 7 CAPSL 0.02764	29	ABCA7	0.02311
28 C3 0.0237 26 NLK 0.0240 19 RNF41 0.0241 8 MICB 0.0244 28 LONP1 0.0250 29 PRSS57 0.0250 10 LINC01004 0.0253 27 HGS 0.0254 33 RTCB 0.0254 31 AZGP1P1 0.0254 31 PCIF1 0.0259 8 NOTCH4 0.0259 30 CBLC 0.0261 25 CHST6 0.026 6 FYB 0.0265 29 CNN2 0.0267 27 SLC25A10 0.0267 24 CX3CL1 0.0269 7 CAPSL 0.0276	10	KMT2E	0.02314
28 C3 0.0237 26 NLK 0.0240 19 RNF41 0.0241 8 MICB 0.0244 28 LONP1 0.0250 29 PRSS57 0.0250 10 LINC01004 0.0253 27 HGS 0.0254 33 RTCB 0.0254 31 PCIF1 0.0254 31 PCIF1 0.0259 8 NOTCH4 0.0259 30 CBLC 0.0261 25 CHST6 0.026 6 FYB 0.0265 29 CNN2 0.0267 27 SLC25A10 0.0267 24 CX3CL1 0.0269 7 CAPSL 0.0276	22	ACTN1	0.02375
26 NLK 0.02403 19 RNF41 0.02413 8 MICB 0.02444 28 LONP1 0.02503 29 PRSS57 0.02507 10 LINC01004 0.02534 27 HGS 0.02543 33 RTCB 0.02544 31 AZGP1P1 0.02544 31 PCIF1 0.02556 7 PRLR 0.02593 8 NOTCH4 0.02593 30 CBLC 0.0261 25 CHST6 0.0265 29 CNN2 0.02674 27 SLC25A10 0.02674 24 CX3CL1 0.02693 7 CAPSL 0.02764	28	СЗ	0.02377
19 RNF41 0.02412 8 MICB 0.02444 28 LONP1 0.02503 29 PRSS57 0.02503 10 LINC01004 0.02536 27 HGS 0.02543 33 RTCB 0.02543 11 AZGP1P1 0.02543 31 PCIF1 0.02543 7 PRLR 0.02593 8 NOTCH4 0.02593 30 CBLC 0.02613 25 CHST6 0.02643 6 FYB 0.026543 29 CNN2 0.026744 29 CNN2 0.026744 27 SLC25A10 0.026744 24 CX3CL1 0.02693 7 CAPSL 0.027644	26	NLK	0.02403
8 MICB 0.0244s 28 LONP1 0.0250s 29 PRSS57 0.0250s 10 LINC01004 0.0253s 27 HGS 0.0254s 33 RTCB 0.0254s 11 AZGP1P1 0.0254s 31 PCIF1 0.0255s 7 PRLR 0.0259s 8 NOTCH4 0.0259s 30 CBLC 0.026f 25 CHST6 0.026f 6 FYB 0.026f 29 CNN2 0.026f 29 CNN2 0.026f 24 CX3CL1 0.026g 7 CAPSL 0.0276s	19	RNF41	0.02412
28 LONP1 0.02503 29 PRSS57 0.02503 10 LINC01004 0.02536 27 HGS 0.02543 33 RTCB 0.02544 11 AZGP1P1 0.02544 31 PCIF1 0.02593 7 PRLR 0.02593 8 NOTCH4 0.02593 30 CBLC 0.02613 25 CHST6 0.02643 6 FYB 0.02653 29 CNN2 0.02674 27 SLC25A10 0.02674 24 CX3CL1 0.02693 7 CAPSL 0.02764	8	MICB	0.02445
29 PRSS57 0.0250 10 LINC01004 0.0253 27 HGS 0.0254 33 RTCB 0.0254 11 AZGP1P1 0.0254 31 PCIF1 0.0259 7 PRLR 0.0259 8 NOTCH4 0.0259 30 CBLC 0.0261 25 CHST6 0.0265 6 FYB 0.0265 29 CNN2 0.0267 27 SLC25A10 0.02679 24 CX3CL1 0.0269 7 CAPSL 0.0276	28	LONP1	0.02503
10 LINCO1004 0.02536 27 HGS 0.02543 33 RTCB 0.02543 11 AZGP1P1 0.02543 31 PCIF1 0.02556 7 PRLR 0.02593 8 NOTCH4 0.02593 30 CBLC 0.0261 25 CHST6 0.0265 6 FYB 0.0265 29 CNN2 0.02674 27 SLC25A10 0.02679 24 CX3CL1 0.02693 7 CAPSL 0.02764	29	PRSS57	0.02507
27 HGS 0.02543 33 RTCB 0.02543 11 AZGP1P1 0.02544 31 PCIF1 0.02593 7 PRLR 0.02593 8 NOTCH4 0.02593 30 CBLC 0.02613 25 CHST6 0.02653 6 FYB 0.02653 29 CNN2 0.02673 27 SLC25A10 0.02673 24 CX3CL1 0.02693 7 CAPSL 0.02763	10	LINC01004	0.02536
11 AZGP1P1 0.0254 31 PCIF1 0.0259 7 PRLR 0.0259 8 NOTCH4 0.0259 30 CBLC 0.0261 25 CHST6 0.0265 6 FYB 0.0265 29 CNN2 0.0267 27 SLC25A10 0.02679 24 CX3CL1 0.0269 7 CAPSL 0.0276	27	HGS	0.02542
31	33	RTCB	0.02543
31 PCIF1 0.02556 7 PRLR 0.02593 8 NOTCH4 0.02593 30 CBLC 0.0261 25 CHST6 0.0265 6 FYB 0.0265 29 CNN2 0.02674 27 SLC25A10 0.02674 24 CX3CL1 0.02693 7 CAPSL 0.02764	11	AZGP1P1	0.02547
8 NOTCH4 0.02598 30 CBLC 0.0261 25 CHST6 0.0265 6 FYB 0.0265 29 CNN2 0.0267 27 SLC25A10 0.0267 24 CX3CL1 0.0269 7 CAPSL 0.0276	31	PCIF1	0.02556
8 NOTCH4 0.02598 30 CBLC 0.0261 25 CHST6 0.0265 6 FYB 0.0265 29 CNN2 0.02674 27 SLC25A10 0.02679 24 CX3CL1 0.02699 7 CAPSL 0.02764	7	PRLR	0.02592
25	8	NOTCH4	0.02598
25 CHST6 0.0267 6 FYB 0.0265 29 CNN2 0.0267 27 SLC25A10 0.0267 24 CX3CL1 0.0269 7 CAPSL 0.0276	30	CBLC	0.02617
6 FYB 0.0265 29 CNN2 0.02674 27 SLC25A10 0.02675 24 CX3CL1 0.02695 7 CAPSL 0.02764	25	CHST6	0.0264
29 CNN2 0.02674 27 SLC25A10 0.02675 24 CX3CL1 0.02695 7 CAPSL 0.02764	6	FYB	0.02651
27 SLC25A10 0.02679 24 CX3CL1 0.02699 7 CAPSL 0.02764	29	CNN2	0.02674
24 CX3CL1 0.02693 7 CAPSL 0.02764	27	SLC25A10	0.02679
7 CAPSL 0.0276	24	CX3CL1	0.02692
2072.505/2	7	CAPSL	0.02764
8 PPT2-EGFL8 0.0276	8	PPT2-EGFL8	0.02765
	8	NRM	0.02772
	34	KCNJ4	0.02772

7	IL7R	0.02779
30	IGSF23	0.02782
8	FLOT1	0.02893
29	AZU1	0.02942
19	ANKRD52	0.02947
11	PILRA	0.02955
8	ATAT1	0.02962
11	EPHB4	0.02972
31	PLTP	0.02988
27	CCDC137	0.03008
27	OXLD1	0.03008
29	STK11	0.03014
20	BRAP	0.03019
19	RDH5	0.03027
12	LOXL2	0.03037
28	PTPRS	0.03047
7	NADK2	0.03069
17	PRTFDC1	0.03085
19	RAB5B	0.03124
26	PROCA1	0.0315
26	NOS2	0.03158
27	NPLOC4	0.03158
33	SLC5A4	0.03166
12	СНМР7	0.03172
7	SPEF2	0.03181
20	ACAD10	0.03248
11	ZAN	0.03257
14	KLF9	0.03261
8	MDC1	0.03274
26	KRT18P55	0.03309
8	PPP1R18	0.03342
24	MT1H	0.03343
28	KHSRP	0.03348
26	POLDIP2	0.03395
18	BTBD16	0.03403
34	CARD10	0.03447
11	MCM7	0.03451
20	PTPN11	0.03456
30	NKPD1	0.03472
<u> </u>		•

24	CCL22	0.03481
6	С9	0.03496
30	RSPH6A	0.0353
11	TFR2	0.03558
34	CDC42EP1	0.03579
27	PCYT2	0.0359
1	DENND1B	0.03598
9	TMEM63B	0.03603
26	SARM1	0.03622
7	UGT3A2	0.03637
34	NOL12	0.03656
24	POLR2C	0.03659
28	EMR1	0.03659
24	PLLP	0.03674
24	MT1G	0.03684
8	HLA-C	0.03748
8	ATF6B	0.03778
12	PEBP4	0.03791
31	ZNF335	0.03801
8	GNL1	0.03826
7	RANBP3L	0.03875
24	RSPRY1	0.03892
33	BPIFC	0.03897
33	RFPL3	0.03904
19	SUOX	0.03917
32	RAB22A	0.0393
30	CKM	0.03938
29	HCN2	0.03973
30	PPP1R37	0.03975
34	ELFN2	0.03983
26	FAM222B	0.04021
8	TAP1	0.04025
19	SARNP	0.04059
24	OGFOD1	0.04059
34	SLC16A8	0.04085
19	OR6C4	0.04093
29	MIDN	0.04104
25	CFDP1	0.04105
18	NSMCE4A	0.04152
		0.01.02

22	DCAF5	0.04154
20	NAA25	0.04157
19	SLC39A5	0.0417
31	NCOA5	0.04177
30	DMWD	0.04185
24	FAM192A	0.04223
28	CLPP	0.04227
20	OAS2	0.04236
2	C2orf83	0.0427
11	GAL3ST4	0.04306
7	UGT3A1	0.04318
8	LTA	0.04333
8	HCG27	0.04337
26	FLOT2	0.04352
23	ALDH1A2	0.0439
25	TMEM170A	0.0439
24	NLRC5	0.04394
23	HSP90AB4P	0.04408
12	TNFRSF10C	0.04477
26	SPAG5	0.04481
5	PLA2G12A	0.04484
28	FUT3	0.04519
20	SH2B3	0.04551
17	ARHGAP21	0.04561
4	DCBLD2	0.0459
8	MUC22	0.04609
25	ZFP1	0.04623
32	PMEPA1	0.04633
18	FAM24B	0.04651
8	HCP5	0.04676
5	CFI	0.04735
34	TRIOBP	0.04743
5	CASP6	0.04754
29	WDR18	0.04767
8	PPP1R10	0.04797
20	ATXN2	0.04812
26	FOXN1	0.04815
10	EFCAB10	0.04819
11	SLC12A9	0.04846
<u> </u>	1	

27	BAHCC1	0.04868
25	WDR59	0.04878
6	OSMR	0.0488
25	MLKL	0.04883
32	VAPB	0.04886
8	HLA-DPA1	0.04963
8	HLA-DPB1	0.04963
8	PRR3	0.04968

Supplementary Table 4:

	Gene	Chr	ВР	OR	95%CI	Р
1	ZNF180	19	44983567	0.2176	[0.04-1.14]	0.001235
2	CFHR5	1	196962502	0.2461	[0.05-1.16]	0.001626
3	GPR128	3	100396915	0.1992	[0.03-1.2]	0.002002
4	KCNT2	1	196348779	0.2226	[0.04-1.2]	0.002353
5	SYN3	22	33001207	5.271	[0.04-1.35]	0.002511
6	LHFPL3	7	104245132	0.1481	[0.01-1.31]	0.003227
7	PSORS1C3	6	31141523	0.2548	[0.05-1.22]	0.003532
8	CDC42EP1	22	37958163	3.541	[0.8-11.68]	0.003643
9	RAB5B	12	56389293	0.3115	[0.08-1.2]	0.003893
10	CMSS1	3	99683653	0.1851	[0.02-1.3]	0.004253
11	FILIP1L	3	99683653	0.1851	[0.02-1.3]	0.004253

12	MIR548G	3	99683653	0.1851	[0.02-1.3]	0.004253
13	RPS26	12	56435929	0.323	[0.02-1.85]	0.004307
14	SUOX	12	56393337	0.3192	[0.52-1.3]	0.004432

Supplementary Table 5:

	Gene	Chr	ВР	OR	95%CI	Р
1	HTRA1	10	124221270	2.221	[1.08-4.58]	2.914E-06
2	ARMS2	10	124215211	2.23	[1.08-4.6]	3.062E-06
3	CFH	1	196673430	1.984	[1.02-3.84]	0.00003481
4	CFHR2	1	196927791	1.931	[1.01-3.68]	0.00006749
5	ZNF557	19	7083629	1.823	[0.98-3.4]	0.0003984
6	SRPK2	7	104877373	0.5753	[0.32-1.03]	0.0005616
7	ТОММ40	19	45396219	-3.424	[0.25-1.04]	0.0006182
8	CFHR5	1	196978615	0.582	[0.32-1.03]	0.0007713
9	HLA-B	6	31324864	0.3546	[0.11-1.08]	0.0009341
10	CFHR4	1	196870299	0.3862	[0.14-1.07]	0.0009646
11	PLEKHA1	10	124139393	1.695	[0.95-3]	0.0009873

544 Related Manuscript File

dbSNP Identifier	HGVS nomenclature	Chr:BP
rs1195500:G>A,C,T	NC_000015.10:g.29394842G>A, NC_000015.10:g.29394842G>C, NC_000015.10:g.29394842G>T	Chr15:29687047 (GRCh37)
rs116928937:C>A	NC_000015.10:g.65385107C>A	Chr15:65677446 (GRCh37)
rs142491581:C>G	NC_000004.12:g.127714391C>G	Chr4:128635546 (GRChr37)
rs6449549:C>T	NC_000005.10:g.61734604C>T	Chr5:61030432 (GRChr37)
rs4235321:G>A	NC_000004.12:g.24954305G>A	Chr4:24955928 (GRChr37)
rs41592:G>A	NC_000007.14:g.83012543G>A	Chr7:82641860 (GRChr37)
rs12701455:A>G,T	NC_000007.14:g.1015773A>G,N C_000007.14:g.1015773A>T	Chr7:1055409 (GRChr37)
rs11689931:T>G	NC_000002.12:g.205576255T>G	Chr2:206440979 (GRChr37)
rs1506825:A>C,T	NC_000016.10:g.76449122A>C,N C_000016.10:g.76449122A>T	Chr16:76483019 (GRChr37)

Gene	dbSNP TopVariant	HGVS	TopVariant:Chr:BP
Gene		11073	•
			(GRChr37)
		NO 000004 44 400700040	
CFH	rs3766405:C>A,T	NC_000001.11:g.196726031C>	Chr1:196695161
		A,NC_000001.11:g.196726031	
		C>T	
		NO 000040 44 - 40045 4000	
ARMS2	rs10490924:G>C,T	NC_000010.11:g.122454932G>	Chr10:124214448
		C,NC_000010.11:g.122454932	
		G>T	
LITDAA		NC_000010.11:g.122461753C>	Cl. 40 42 4224270
HTRA1	rs1049331:C>T	T	Chr10:124221270
		'	
CFHR5	rs10922153:T>G	NC_000001.11:g.197009484T>	Chr1:196978615
CITIKS	1310322133.170	G	CIII 1.130378013
CFHR2	rs2026547:G>A	NC_000001.11:g.196958661G>	Chr1:196927791
		Α	
CFHR4	rs34833349:A>G	NC_000001.11:g.196901169A>	Chr1:196870299
		G	

KCNT2	rs10922068:T>A,C	NC_000001.11:g.196437585T> A,NC_000001.11:g.196437585 T>C	Chr1:196406715
F13B	rs10754210:G>A	NC_000001.11:g.197042981G> A	Chr1:197012111
SYN3	rs5754187:C>T	NC_000022.11:g.32651611C>T	Chr22:33047598
ASPM	rs6676084:C>T	NC_000001.11:g.197124900C> T	Chr1:197094030
ZBTB41	rs4350226:G>A,C,T	NC_000001.11:g.197163247G> A,NC_000001.11:g.197163247 G>C,NC_000001.11:g.1971632 47G>T	Chr1:197132378
PLEKHA1	rs2421017:A>G	NC_000010.11:g.122388651A> G	Chr10:124148167
VPS29	rs184629901:T>C	NC_000012.12:g.110497463T> C	Chr12:110935268
CRB1	rs12737179:T>C,G	NC_000001.11:g.197230303T> C,NC_000001.11:g.197230303 T>G	Chr1:197199434
PPTC7	rs56159960:T>C	NC_000012.12:g.110556262T> C	Chr12:110994068
ZNF557	rs966591:A>C,G	NC_000019.10:g.7083618A>C, NC_000019.10:g.7083618A>G	Chr19: 7083629
HVCN1	rs73191857:C>T	NC_000012.12:g.110661916C> T	Chr12: 111099721
MICALL1	rs9607501:G>A,C,T	NC_000022.11:g.37922890G> A,NC_000022.11:g.37922890G >C,NC_000022.11:37922890G >T	Chr22: 38318897
SMC5	rs66524845:A>G	NC_000009.12:g.70305808A> G	Chr9: 72920724
PPP1CC	rs1973505:G>A	NC_000012.12:g.110722198G> A	Chr12: 111160003
TCTN1	rs7953794:A>G	NC_000012.12:g.110643392A> G	Chr12: 111081197
HLA-B	rs151341076:G>A,C,T	NC_000006.12:g.31357087G:A, NC_000006.12:g.31357087G> C,NC_000006.12:g. 31357087G>T	Chr6:31324864

CFHR5	rs7547265:G>C,T	NC_000001.11:g.196993372G> C,NC_000001.11:g.196993372 G>T	Chr1: 196962502
GPR128	rs7629279:G>T	NC_000003.12:g.100678070G> T	Chr3:100396915
KCNT2	rs7527415:C>T	NC_000001.11:g.196379649C>	Chr1:196348779
LHFPL3	rs17139096:A>G,T	NC_000007.14:g.104604684A> G,NC_000007.14:g.104604684 A>T	Chr7:104245132
PSORS1C 3	rs887468:C>T	NC_000006.12:g.31173746C>T	Chr6:31141523
CDC42EP	rs2235335:G>A,C	NC_000022.11:g.37562156G> A,NC_000022.11:g.37562156G >C	Chr22:37958163
RAB5B	rs705700:T>A,C	NC_000012.12:g.55995509T>A ,NC_000012.12:g.55995509T> C	Chr12:56389293
FILIP1L	rs73138610:C>A,G	NC_000003.12:g.99964809C>A ,NC_000003.12:g.99964809C> G	Chr3:99683653
RPS26	rs1131017:C>A,G,T	NC_000012.12:g.56042145C>A ,NC_000012.12:g.56042145C> G,NC_000012.12:g. 56042145C>T	Chr12:56435929
SUOX	rs1081975:C>A,G	NC_000012.12:g.55999553C>A ,NC_000012.12:g.55999553C> G	Chr12:56393337
HTRA1	rs1049331:C>T	NC_000010.11:g.122461753C> T	Chr10:124221270
ARMS2	rs36212733:T>A,C,G	NC_000010.11:g.122455695T> A,NC_000010.11:g.122455695 T>C,	Chr10:124215211
		NC_000010.11:g.122455695T> G	
CFH	rs9970075:T>A,G	NC_000001.11:g.196704299T> A,NC_000001.11:g.196704299 T>G	Chr1:196673430
CFHR2	rs2026547:G>A	NC_000001.11:g.196958661G> A	Chr1:196927791

ZNF557	rs966591:A>C,G	NC_000019.10:g.7083618A>C, NC_000019.10:g.7083618A>G	Chr19:7083629
SRPK2	rs6950104:G>A,C	NC_000007.14:g.105236926G> A,NC_000007.14:g.105236926 G>C	Chr7:104877373
TOMM4 0	rs157582:C>T	NC_000019.10:g.44892961C>T	Chr19:45396219
CFHR5	rs10922153:T>G	NC_000001.11:g.197009484T> G	Chr1:196978615
HLA-B	rs151341076:G>A,C,T	NC_000006.12:g.31357087G> A,NC_000006.12:g.31357087G >C,	Chr6:31324864
		NC_000006.12:g.31357087G>T	
CFHR4	rs34833349:A>G	NC_000001.11:g.196901169A> G	Chr1:196870299
PLEKHA1	rs11200594:C>G,T	NC_000010.11:g.122379876C> G,NC_000010.11:g.122379876 C>T	Chr10:124139393